Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
Abstract The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join â it's freeAlready a member? Log in